Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

References

• Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N. Engl. J. Med.332(15), 1004–1014 (1995).
   PubMed Web of Science ®Google Scholar
• Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J. Pharmacol. Exp. Ther.268(2), 1051–1056 (1994).
   PubMed Web of Science ®Google Scholar
• Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res.887(2), 239–249 (2000).
   PubMed Web of Science ®Google Scholar
• Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D’Incalci M. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin [see comments]. Ann. Oncol.10(4), 391–395 (1999).
   PubMed Web of Science ®Google Scholar
• van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs19(2), 125–141 (2001).
   PubMed Web of Science ®Google Scholar
• Soepenberg O, Sparreboom A, de Jonge MJ et al. Real-time pharmacokinetics guiding clinical decisions; Phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. Eur. J. Cancer40(5), 681–688 (2004).
   PubMedGoogle Scholar
• Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov.2(5), 347–360 (2003).
   PubMed Web of Science ®Google Scholar
• Garfield D. New form of paclitaxel shows promise. Lancet Oncol.2(4), 192 (2001).
   PubMedGoogle Scholar
• Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm.235(1–2), 179–192 (2002).
   PubMed Web of Science ®Google Scholar
• Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. Macmillan Co., New York, NY, USA (1966).
   Google Scholar
• Frei III EF, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am. J. Med.69, 585–594 (1980).
   PubMed Web of Science ®Google Scholar
• Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J. Clin. Oncol.15(8), 2981–2995 (1997).
   PubMed Web of Science ®Google Scholar
• Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality? Bone Marrow Transplant.35(3), 215–224 (2005).
   PubMed Web of Science ®Google Scholar
• Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl Cancer Inst.90(16), 1205–1211 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Wickerham DL et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin–cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J. Clin. Oncol.15(5), 1858–1869 (1997).
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, DeCillis A et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from national surgical adjuvant breast and bowel project B-25. J. Clin. Oncol.17(11), 3374–3388 (1999).
   PubMed Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol.21(6), 976–983 (2003).
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Buzdar AU, Theriault RL et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J. Natl Cancer Inst.92(3), 225–233 (2000).
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, O’Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N. Engl. J. Med.342(15), 1069–1076 (2000).
   PubMed Web of Science ®Google Scholar
• Schrama JG, Faneyte IF, Schornagel JH et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann. Oncol.13(5), 689–698 (2002).
   PubMedGoogle Scholar
• Rodenhuis S, Bontenbal M, Beex LV et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N. Engl. J. Med.349(1), 7–16 (2003).
   PubMed Web of Science ®Google Scholar
• Leonard RC, Lind M, Twelves C et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J. Natl Cancer Inst.96(14), 1076–1083 (2004).
   PubMed Web of Science ®Google Scholar
• Zander AR, Kroger N, Schmoor C et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J. Clin. Oncol.22(12), 2273–2283 (2004).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Howell A, Emson M et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann. Oncol.16(5), 726–734 (2005).
   PubMed Web of Science ®Google Scholar
• Nitz UA, Mohrmann S, Fischer J et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre Phase III trial. Lancet366(9501), 1935–1944 (2005).
   PubMed Web of Science ®Google Scholar
• Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J. Clin. Oncol.23(10), 2191–2200 (2005).
   PubMed Web of Science ®Google Scholar
• Schmid P, Schippinger W, Nitsch T et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J. Clin. Oncol.23(3), 432–440 (2005).
   PubMed Web of Science ®Google Scholar
• Winer EP, Berry DA, Woolf S et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J. Clin. Oncol.22(11), 2061–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Presant CA, Wolf W, Waluch V et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet343(8907), 1184–1187 (1994).
   PubMed Web of Science ®Google Scholar
• Muller M, Mader RM, Steiner B et al. 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res.57(13), 2598–2601 (1997).
   PubMed Web of Science ®Google Scholar
• Muller M, Brunner M, Schmid R et al. Interstitial methotrexate kinetics in primary breast cancer lesions. Cancer Res.58(14), 2982–2985. (1998).
   PubMedGoogle Scholar
• Muller M, Bockenheimer J, Zellenberg U et al. Relationship between in vivo drug exposure of the tumor interstitium and inhibition of tumor cell growth in vitro: a study in breast cancer patients. Breast Cancer Res. Treat.60(3), 211–217 (2000).
   PubMed Web of Science ®Google Scholar
• Robert NJ, Vogel CL, Henderson IC et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin. Oncol.31(6 Suppl. 13), 106–146 (2004).
   PubMed Web of Science ®Google Scholar
• Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J. Clin. Oncol.21(4), 588–592 (2003).
   PubMed Web of Science ®Google Scholar
• Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol.18(4), 724–733 (2000).
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol.21(8), 1431–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Jones SE, Erban J, Overmoyer B et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol.23(24), 5542–5551 (2005).
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med.352(22), 2302–2313 (2005).
   PubMed Web of Science ®Google Scholar
• Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J. Clin. Oncol.24(36), 5664–5671 (2006).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Seidman A, Berry D, Cirrincione C et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc. Am. Soc. Clin. Oncol.23, A512 (2004).
   Google Scholar
• Tabernero J, Climent MA, Lluch A et al. A multicentre, randomised Phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann. Oncol.15(9), 1358–1365 (2004).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Martino S et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. In: 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–11 December 2005 (Abstract 48).
   Google Scholar
• Brouwer E, Verweij J, De Bruijn P et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab. Dispos.28(10), 1141–1145 (2000).
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer37(13), 1590–1598 (2001).
   PubMed Web of Science ®Google Scholar
• Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D. Measurement of cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl Cancer Inst.85(20), 1685–1690 (1993).
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res.8(5), 1038–1044 (2002).
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Scripture CD, Trieu V et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res.11(11), 4136–4143 (2005).
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res.12(4), 1317–1324 (2006).
   PubMed Web of Science ®Google Scholar
• Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev.6(4), 559–593 (1987).
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA95(8), 4607–4612 (1998).
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park)19(4 Suppl. 3), 7–16 (2005).
   PubMedGoogle Scholar
• Schubert W, Frank PG, Razani B, Park DS, Chow CW, Lisanti MP. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J. Biol. Chem., 276(52), 48619–48622 (2001).
   PubMed Web of Science ®Google Scholar
• Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot. Essent. Fatty Acids72(4), 267–272 (2005).
   PubMed Web of Science ®Google Scholar
• Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest.115(6), 1492–1502 (2005).
   PubMed Web of Science ®Google Scholar
• Shi Q, Bao S, Bigner D Jr. Secreted protein acidic and rich in cysteine (SPARC) activates focal adhesion kinase and integrin-linked kinase to induce AKT-dependent glioma survival and invasion. Presented at: 97th Annual Meeting of the American Association of Cancer Research (AACR), Washington, DC, USA, 1–5 April 2006 (17 Abstract 1683).
   Google Scholar
• Desai N, Trieu V, Yao R, Frankel T, Soon-Shiong P. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Presented at: 26th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 3–6 December 2004 (Abstract 206).
   Google Scholar
• Trieu V, Damascelli B, Soon-Shiong P, Desai N. SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab paclitaxel, ABI-007, Abraxane). Presented at: 97th Annual Meeting of the American Association of Cancer Research (AACR). Washington, DC, USA, 1–5 April 2006 (17 Abstract 4477).
   Google Scholar
• Nyman DW, Campbell KJ, Hersh E et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol.23(31), 7785–7793 (2005).
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Zuylen L, Brouwer E et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res.59(7), 1454–1457 (1999).
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yang A et al. Enhanced efficacy and safety of nanoparticle albumin-bound nab-docetaxel versus taxotere. Presented at: 97th Annual Meeting of the American Association of Cancer Research (AACR). Washington, DC, USA, 1–5 April 2006 (17 Abstract 5438).
   Google Scholar
• Teng XY, Guan Z, Yao Z et al. A tolerability study of a cremophor-free, nanoparticle albumin bound paclitaxel intravenously administered in Chinese patients with advanced solid tumor. Proc. Am. Soc. Clin. Oncol.24 (2005) (Abstract 5571).
   Google Scholar
• Ibrahim NK, Samuels B, Page R et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol.23(25), 6019–6026 (2005).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JA, Blum JL, Sandbach JF, Savin M, Fenske E, Hawkins MJ. Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. In: 27th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–11 December 2004 (Abstract 1070).
   Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol.23(31), 7794–7803 (2005).
   PubMed Web of Science ®Google Scholar
• Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Hawkins MJ. A randomized Phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract 46).
   Google Scholar
• Hudis C, Citron M, Berry D et al. Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Presented at: 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–11 December 2005 (Abstract 41).
   Google Scholar
• Robert N, Ambro S, Krekow L et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. Presented at: 28th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8–11 December 2005 (Abstract 2073).
   Google Scholar
• Seidman AD, Danso M, Bach A et al. Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer. J. Clin. Oncol. (Meeting Abstracts), 24(18 Suppl.), (2006) (Abstract 10650).
   Google Scholar
• Yardley DA, Meluch A, Murphy P et al. Preliminary results from a multicenter Phase II trial of biweekly neoadjuvant gemcitabine, epirubicin, ABI-007 (GEA) with correlative SPARC tumor analysis. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract 3069).
   Google Scholar
• Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin. Breast Cancer6(4), 361–364 (2005).
   PubMedGoogle Scholar
• Link JS, Waisman JR, Jacobs CI. Bevacizumab (Avastin) and albumin bound paclitaxel (Abraxane) treatment in metastatic breast cancer. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006 (Abstract 1095).
   Google Scholar
• Smith RE, Brown AM, Mamounas EP et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J. Clin. Oncol.17(11), 3403–3411 (1999).
   PubMed Web of Science ®Google Scholar
• Abraxane®, Package Insert. Abraxis Oncology, a division of the American Pharmaceutical Partners, Inc. Schaumburg, IL, USA.
   Google Scholar